ロード中...
Immune dysregulation as a driver of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) affects hundreds of thousands of people worldwide, reducing their quality of life and leading to death from respiratory failure within years of diagnosis. Treatment options remain limited, with only two FDA-approved drugs available in the United States, neither of...
保存先:
| 出版年: | J Clin Invest |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Clinical Investigation
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7810481/ https://ncbi.nlm.nih.gov/pubmed/33463535 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI143226 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|